Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 5/20 | 0.55 |
| ▸ | CES1 | P23141 | 5/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.52 |
| ▸ | ESR1 | P03372 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8412560 | 0.93 | CES2 (0.57) | CES2CES1PTGS2ESR1HSD17B3 | |
| SCHEMBL3734266 | 0.85 | HSD17B3 (0.56) | PTGS2ESR1ALDH1A1HSD17B3ESR2 | |
| SCHEMBL27798133 | 0.81 | HTR7 (0.56) | CES2CES1PTGS2ESR1HSD17B3 | |
| SCHEMBL27798187 | 0.81 | HDAC3 (0.41) | CES2CES1ESR1ALDH1A1HSD17B3 | |
| SCHEMBL4712635 | 0.81 | ESR2 (0.42) | CES2CES1ESR1ESR2 | |
| SCHEMBL7860414 | 0.81 | LMNA (0.51) | PTGS2ALDH1A1 | |
| SCHEMBL27819250 | 0.80 | HDAC1 (0.47) | CES2CES1PTGS2ESR1ALDH1A1 | |
| SCHEMBL27819249 | 0.79 | USP5 (0.40) | CES2CES1ESR1HSD17B3ESR2 | |
| SCHEMBL27819285 | 0.79 | ABAT (0.39) | CES2CES1ESR1ALDH1A1HSD17B3 | |
| SCHEMBL28026476 | 0.77 | LOXL2 (0.45) | CES2CES1PTGS2ESR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117630081-A | Detection method of water free radical cations | 电子科技大学 | 2024-03-01 | — | — | CN | claimed |
| CN-117480654-A | Secondary battery, battery module, battery pack, and electricity device | 宁德时代新能源科技股份有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-116941085-A | Secondary battery, battery module, battery pack, and electricity device | 宁德时代新能源科技股份有限公司 | 2023-10-24 | — | — | CN | claimed |
| EP-3340972-A1 | METHOD OF TRANSPORTING AN AGENT ACROSS BLOOD-BRAIN, BLOOD-COCHLEAR OR BLOOD-CEREBROSPINAL FLUID BARRIER | Oklahoma Medical Research Foundation (US) | 2018-07-04 | — | — | EP | claimed |
| EP-2056783-B1 | HAIR CARE COMPOSITIONS THAT CAN INCREASE THE APPEARANCE OF THICKER AND FULLER HAIR | PROCTER & GAMBLE (US) | 2017-11-22 | — | — | EP | claimed |
| WO-2017048778-A1 | METHOD OF TRANSPORTING AN AGENT ACROSS BLOOD-BRAIN, BLOOD-COCHLEAR OR BLOOD-CEREBROSPINAL FLUID BARRIER | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2017-03-23 | — | — | WO | claimed |
| CN-105796602-A | Treatment of stroke using isolated placental cells | 人类起源公司 | 2016-07-27 | — | — | CN | claimed |
| EP-2574328-A2 | Hair care compositions, methods, and articles of commerce that can increase the appearance of thicker and fuller hair | The Procter and Gamble Company (US) | 2013-04-03 | — | — | EP | claimed |
| US-20120258185-A1 | HAIR CARE COMPOSITIONS, METHODS, AND ARTICLES OF COMMERCE THAT CAN INCREASE THE APPEARANCE OF THICKER AND FULLER HAIR | OBLONG JOHN ERICH (US) | 2012-10-11 | — | — | US | claimed |
| CN-102186971-A | Treatment of stroke using isolated placental cells | ANTHROGENESIS CORP | 2011-09-14 | — | — | CN | claimed |
| US-RE35213-E | Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1996-04-16 | — | — | US | claimed |
| US-RE35112-E | Administering phenyl butyl nitrone or derivative in carrier in dosage to prevent or reverse oxidative central nervous system tissue damage | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1995-12-05 | — | — | US | claimed |
| EP-0496796-B1 | METHOD AND COMPOSITIONS FOR INHIBITION OF DISORDERS ASSOCIATED WITH OXIDATIVE DAMAGE | OKLAHOMA MED RES FOUND (US) | 1994-08-31 | — | — | EP | claimed |
| EP-0518951-A4 | PHENYL BUTYL NITRONE COMPOSITIONS FOR PREVENTION OF GASTRIC ULCERATION | — | 1993-02-24 | — | — | EP | claimed |
| EP-0518951-A1 | PHENYL BUTYL NITRONE COMPOSITIONS FOR PREVENTION OF GASTRIC ULCERATION | Oklahoma Medical Research Foundation (US) | 1992-12-23 | — | — | EP | claimed |
| EP-0496796-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF DISORDERS ASSOCIATED WITH OXIDATIVE DAMAGE. | OKLAHOMA MED RES FOUND (US) | 1992-08-05 | — | — | EP | claimed |
| WO-1991013618-A1 | PHENYL BUTYL NITRONE COMPOSITIONS FOR PREVENTION OF GASTRIC ULCERATION | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1991-09-19 | — | — | WO | claimed |
| US-5036097-A | Antiinflammatory agents/non-steriodal | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1991-07-30 | — | — | US | claimed |
| US-5025032-A | For ischemia or inflammation of brain or nervous system | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1991-06-18 | — | — | US | claimed |
| WO-1991005552-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF DISORDERS ASSOCIATED WITH OXIDATIVE DAMAGE | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1991-05-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258185-A1 | HAIR CARE COMPOSITIONS, METHODS, AND ARTICLES OF COMMERCE THAT CAN INCREASE THE APPEARANCE OF THICKER AND FULLER HAIR | SHH, FSCN1, CUTA | CES2 1690/4885CES1 3525/4885PTGS2 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.